Tokuno Masahiro, Taguchi Kazuaki, Yamasaki Keishi, Sakai Hiromi, Otagiri Masaki
Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
DDS Research Institute, Sojo University, Kumamoto, Japan.
PLoS One. 2016 Oct 31;11(10):e0165557. doi: 10.1371/journal.pone.0165557. eCollection 2016.
Hemoglobin-vesicles (HbV), encapsulating highly concentrated human hemoglobin in liposomes, were developed as a substitute for red blood cells (RBC) and their safety and efficacy in transfusion therapy has been confirmed in previous studies. Although HbV suspensions are structurally and physicochemically stabile for least 1-year at room temperature, based on in vitro experiments, the issue of whether the use of long-term stored HbV after a massive hemorrhage can be effective in resuscitations without adverse, post-transfusion effects remains to be clarified. We report herein on a comparison of the systemic response and the induction of organ injuries in hemorrhagic shock model rats resuscitated using 1-year-stored HbV, freshly packed RBC (PRBC-0) and by 28-day-stored packed RBC (PRBC-28). The six-hour mortality after resuscitation was not significantly different among the groups. Arterial blood pressure and blood gas parameters revealed that, using HbV, recovery from the shock state was comparable to that when PRBC-0 was used. Although no significant change was observed in serum parameters reflecting liver and kidney injuries at 6 hours after resuscitation among the three resuscitation groups, results based on Evans Blue and protein leakage in bronchoalveolar lavage fluid, the lung wet/dry weight ratio and histopathological findings indicated that HbV as well as PRBC-0 was less predisposed to result in a post-transfusion lung injury than PRBC-28, as evidenced by low levels of myeloperoxidase accumulation and subsequent oxidative damage in the lung. The findings reported herein indicate that 1-year-stored HbV can effectively function as a resuscitative fluid without the induction of post-transfused lung injury and that it is comparable to fresh PRBC, suggesting that HbV is a promising RBC substitute with a long shelf-life.
血红蛋白囊泡(HbV)是将高浓度人血红蛋白包裹于脂质体中制成的,被开发用作红细胞(RBC)的替代品,其在输血治疗中的安全性和有效性已在先前研究中得到证实。尽管基于体外实验,HbV悬浮液在室温下结构和物理化学性质至少1年内是稳定的,但大量出血后使用长期储存的HbV进行复苏是否能有效且无输血后不良影响这一问题仍有待阐明。我们在此报告了在失血性休克模型大鼠中,使用储存1年的HbV、新鲜包装的红细胞(PRBC - 0)和储存28天的包装红细胞(PRBC - 28)进行复苏后,全身反应和器官损伤诱导情况的比较。复苏后6小时的死亡率在各组之间无显著差异。动脉血压和血气参数显示,使用HbV时,从休克状态恢复的情况与使用PRBC - 0时相当。尽管在三个复苏组中,复苏后6小时反映肝和肾损伤的血清参数未观察到显著变化,但基于伊文思蓝和支气管肺泡灌洗液中的蛋白质渗漏、肺湿/干重比以及组织病理学结果表明,与PRBC - 28相比,HbV以及PRBC - 0导致输血后肺损伤的倾向较小,肺中髓过氧化物酶积累水平低及随后的氧化损伤证明了这一点。本文报道的研究结果表明,储存1年的HbV可有效作为复苏液,且不会诱导输血后肺损伤,其与新鲜PRBC相当,这表明HbV是一种有前景的、保质期长的红细胞替代品。